MindWalk (NASDAQ:HYFT) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of MindWalk (NASDAQ:HYFT) from a hold rating to a strong sell rating in a report released on Tuesday morning,Zacks.com reports.

A number of other equities analysts also recently commented on the company. Wall Street Zen downgraded MindWalk from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. JonesTrading assumed coverage on shares of MindWalk in a report on Thursday, April 16th. They issued a “buy” rating and a $5.00 target price on the stock. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research note on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, MindWalk presently has an average rating of “Hold” and an average price target of $5.00.

MindWalk Trading Down 1.8%

Shares of NASDAQ HYFT opened at $1.33 on Tuesday. The firm has a market capitalization of $62.36 million, a PE ratio of -6.07 and a beta of 0.83. The company has a fifty day moving average of $1.56. MindWalk has a 12-month low of $0.99 and a 12-month high of $3.25. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.72 and a current ratio of 2.80.

MindWalk (NASDAQ:HYFT) last released its earnings results on Wednesday, July 22nd. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%.The company had revenue of $3.03 million for the quarter. On average, equities analysts forecast that MindWalk will post -0.21 EPS for the current fiscal year.

Institutional Investors Weigh In On MindWalk

Several hedge funds and other institutional investors have recently made changes to their positions in HYFT. Virtu Financial LLC purchased a new stake in MindWalk during the fourth quarter worth approximately $51,000. Bridgeway Capital Management LLC purchased a new position in MindWalk in the fourth quarter valued at approximately $91,000. Bank of Montreal Can increased its stake in MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock valued at $100,000 after purchasing an additional 24,500 shares during the last quarter. XTX Topco Ltd raised its holdings in MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after purchasing an additional 44,331 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after purchasing an additional 96,018 shares in the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.